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Abstract.13
Background: Urate and homocysteine are potential biomarkers for disease progression in Parkinson’s disease (PD). Baseline
serum urate concentration has been shown to predict motor but not cognitive decline. The relationship between serum
homocysteine concentration and cognitive and motor impairment is unknown.
14
15
16
Objectives: The aim of this study was to examine the association between baseline serum urate and homocysteine, and
prospective measures of disease progression and cognition over 54 months in early PD.
17
18
Methods: 154 newly diagnosed PD participants and 99 age-matched controls completed a schedule of assessments at baseline,
18, 36 and 54 months. The Movement Disorders Society Unified Parkinson’s Disease Scale Part III (MDS-UPDRS III) was
used to assess motor severity. The Montreal Cognitive Assessment (MoCA) was used to assess global cognition. Serum
samples drawn at baseline were analysed for urate, homocysteine, red cell folate and vitamin B12 concentrations.
19
20
21
22
Results: Baseline urate was 331.4 ± 83.8 and 302.7 ± 78.0mol/L for control and PD participants, respectively (p = 0.015).
Baseline homocysteine was 9.6 ± 3.3 and 11.1 ± 3.8mol/L for controls and PD participants, respectively (p < 0.01). Linear
mixed effects modelling showed that lower baseline urate (= 0.02, p < 0.001) and higher homocysteine (= 0.29, p < 0.05)
predicted decline in motor function. Only higher homocysteine concentrations at baseline, however, predicted declining
MoCA scores over 54 months (= 0.11, p < 0.01).
23
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Conclusions: Lower serum urate concentration is associated with worsening motor function; while higher homocysteine
concentration is associated with change in motor function and cognitive decline. Therefore, urate and homocysteine may be
suitable biomarkers for predicting motor and cognitive decline in early PD.
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INTRODUCTION 32
Parkinson’s disease (PD) is a progressive neurode- 33
generative disorder encompassing motor, cognitive 34
and behavioural and autonomic features. There is 35
growing evidence that oxidative stress is involved 36
in the pathophysiology, disease progression and 37
ISSN 1877-7171/19/$35.00 © 2019 – IOS Press and the authors. All rights reserved
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development of cognitive impairment in PD.38
Dopaminergic neurons in the basal ganglia are par-39
ticularly susceptible to oxidative stress [1] and the40
post-mortem brains of PD subjects have higher con-41
centrations of the products of oxidative stress than42
controls [2].43
Both urate and homocysteine may have a role in44
regulating oxidative stress in PD. Urate is a prod-45
uct of purine breakdown, which accounts for 60% of46
serum antioxidant capacity [3]. Prospective studies47
have shown that low serum urate in middle age is48
associated with an increased risk of developing PD49
over the subsequent 15–20 years, with participants in50
the lowest quartile 2.3–2.5 times as likely to develop51
the condition than those in the highest quartile [4,52
5]. Furthermore, amongst patients with newly diag-53
nosed PD who had not yet started treatment, those54
with the highest quintile of urate were half as likely55
to require treatment than those in the lowest quin-56
tile over the following two years [6]. Low plasma57
urate in PD patients has also been associated with58
poorer performance in neuropsychological tests sen-59
sitive to attention, executive function and visuospatial60
function [7], suggesting it may be associated with61
cognitive impairment.62
The association between hyperhomocysteinaemia63
and risk of dementia in community dwelling older64
adults has been previously reported [8], raising65
the possibility that it may also have a role in the66
development of PD dementia (PDD). In established67
PD, cross-sectional studies have reported that ele-68
vated plasma homocysteine levels are associated with69
dementia [9].70
The aim of this study was to examine the associa-71
tion between baseline serum urate and homocysteine72
and measures of disease progression in early PD using73
participants in an incident cohort study with prospec-74
tive follow up. We hypothesised that PD patients with75
low urate and/or high homocysteine at baseline would76
display a more rapid decline in motor and cognitive77
function over the 54 month follow up.78
PARTICIPANTS AND METHODS79
Subjects80
Participants were recruited prospectively as part81
of the Incidence of Cognitive Impairment in Cohorts82
with Longitudinal Evaluation in Parkinson’s disease83
(ICICLE-PD) study [10] Inclusion criteria com-84
prised a diagnosis of idiopathic PD according to UK85
Brain Bank Criteria [11] in the North East of Eng-86
land between 1 June 2009 and 31 December 2011. 87
Exclusion criteria were: significant cognitive impair- 88
ment at presentation (Mini Mental State Examination 89
(MMSE) score <24) or a diagnosis of dementia, 90
parkinsonism due to another cause, insufficient work- 91
ing knowledge of English, major psychiatric illness 92
or treatment with COMT inhibitors. 93
To generate normative values, age-matched 94
healthy control subjects were recruited from local 95
advertising and community sources. Carers and 96
spouses of patients with PD were not approached 97
to act as controls to limit bias. Exclusion criteria 98
for controls were: significant cognitive impairment at 99
presentation (MMSE <24) or diagnosis of dementia, 100
major psychiatric illness or movement disorder. 101
The study was approved by Newcastle and North 102
Tyneside Research Ethics Committee. All partic- 103
ipants provided written informed consent at each 104
review. 105
Assessments 106
Demographic information including age, sex, and 107
education were collected. All subjects underwent a 108
medical assessment by a movement disorders special- 109
ist; we sought details of disease duration, co-morbid 110
diseases, medication use, smoking history and alco- 111
hol consumption. Patients were evaluated in the “on” 112
motor state. Motor severity was rated using the Move- 113
ment Disorders Society Unified Parkinson’s Disease 114
Rating Scale (MDS-UPDRS) Part III [12] and Hoehn 115
and Yahr scale [13]. MDS-UPDRS scores range from 116
0–132, with higher scores indicating more severe 117
motor symptoms. Levodopa equivalent daily dose 118
(LEDD) was calculated for all dopaminergic med- 119
ications [14]. Participants completed the National 120
Adult Reading Test (NART) [15] as a measure of 121
pre-morbid IQ and the Geriatric Depression Scale 122
(GDS) [16] was used to measure depressive symp- 123
toms. Global cognitive function was assessed with the 124
Mini-Mental State Examination (MMSE) [17] and 125
Montreal Cognitive Assessment (MoCA). Both tests 126
have a maximum score of 30 with a score of <26 sug- 127
gesting cognitive impairment. The MoCA has been 128
validated in patients with PD [18]. Assessments were 129
repeated at 18-month intervals. 130
Laboratory analyses 131
A single baseline non-fasting blood sample was 132
obtained for measurements of total serum urate, 133
plasma homocysteine, vitamin B12 and red cell folate 134
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concentrations. A serum separate tube (SST) was col-135
lected for urate analysis, which was later determined136
using an enzymatic (Uricase) method on the Roche137
Modular P. Homocysteine samples were collected138
into citrate plasma tubes and put on ice immediately.139
Total plasma homocysteine was measured using an140
automated latex immunoassay (Hemosil, Homocys-141
teine, Instrumentation Laboratory) on the IL-TOP142
Coagulation analyser. Vitamin B12 and red cell folate143
samples were collected into EDTA plasma tubes;144
levels were determined using a chemiluminescent145
microparticle assay (Architect, Abbott).146
Statistical analyses147
Data were analysed using SPSS (Version 21,148
Armonk, NY: IBM Corp). Data were examined149
for normality by visual inspection of histograms150
and Kolmogorov-Smirnov testing. Comparison of151
means between PD and control subjects at baseline152
were performed using independent t-tests or Mann-153
Whitney U tests as appropriate. For comparisons of154
repeated measures between baseline and 54 months,155
repeated measures ANOVA or Friedman tests were156
used as appropriate. Chi-squared testing was used157
to assess binary outcome variables. The signifi-158
cance level for all statistical tests was set at = 0.05159
(two-tailed).160
R [19] and lme4 [20] were used to perform lin-161
ear mixed effects analysis. A random intercept model162
was used to determine baseline predictors of change163
in motor severity and global cognition from base-164
line to 54 months in PD subjects. The intercept165
varied at the participant and time level, accounting166
for by-subject and by-time variability. A reduced167
model was produced by excluding non-significant168
predictors to which baseline serum urate or baseline169
plasma homocysteine were then added, in addition170
to baseline folate and vitamin B12 and their inter-171
actions with time as covariates. Baseline age, sex,172
LEDD, time, age × time and LEDD × time were173
entered into the model as fixed factors predicting174
change in PD motor severity. Baseline age, sex,175
years of education, LEDD, MDS-UPDRS III, GDS-176
15 and time were added as fixed factors predicting177
change in MoCA score, as well as interactions of178
time with baseline age (age × time), motor severity179
(MDS-UPDRS III × time), LEDD (LEDD × time)180
and GDS-15 (GDS-15 × time). LEDD was controlled181
for in all models that included total plasma homo-182
cysteine (tHyc). To account for confounders that183
may mediate the relationship between urate and/or184
tHyc, we repeated the above analysis adjusting for 185
the presence of baseline smoking status, type II dia- 186
betes, hypertension, ischemic heart disease, previous 187
stoke or transient ischemic attack (TIA), hyperc- 188
holesterolemia and gout. Visual inspection of residual 189
plots did not reveal any obvious deviations from 190
homoscedasticity or normality. Fit of the models was 191
assessed by likelihood ratio tests. 192
RESULTS 193
After exclusions, at baseline 154 patients with 194
PD and 99 healthy control subjects completed 195
assessments (Fig. 1). The demographic and clini- 196
cal characteristics of the PD participants and control 197
subjects at baseline were compared (Table 1). Mean 198
time from PD diagnosis was 6.3 ± 6.1 months. There 199
were no significant differences between PD partici- 200
pants and controls with regard to age, sex, years of 201
education or smoking status (p > 0.05 for all). Pre- 202
vious stroke or TIAs were more common in those 203
with PD than controls (10 vs. 0 patients, p < 0.01), 204
but there were no differences in rates of ischaemic 205
heart disease, hypertension, hypercholesterolaemia, 206
gout or type 2 diabetes. PD participants scored sig- 207
nificantly poorer on both the MoCA and MMSE as 208
measures of global cognition (p < 0.01 for both). At 209
54 month evaluation n = 91 PD participants (58%) 210
and 69 control participants (68%) returned (Fig. 1). 211
In total, 18 PD participants declined further follow 212
up, 35 were lost to follow up and 10 were deceased. 213
There were no significant differences in either PD 214
or control subjects who completed all assessments 215
compared those who did not, in terms of baseline 216
age, NART scores, GDS-15, LEDD, MMSE, urate 217
or homocysteine concentrations (p > 0.05 for all). 218
At baseline completers had completed more years 219
of education (13.3 ± 3.8 vs. 12.0 ± 3.7, Z = –2.3, 220
p = 0.024), a lower UPDRS III score (24.2 ± 10.5 221
vs. 30.8 ± 13.2, Z = –3.1, p = 0.002) and higher 222
MoCA score (25.8 ± 3.3 vs. 24.3 ± 3.9, Z = –2.4, 223
p = 0.018). 224
CHANGES IN SERUM URATE AND 225
HOMOCYSTEINE 226
Total plasma urate concentration was signifi- 227
cantly lower in those with PD than in controls 228
at baseline (302.7 ± 77.9 vs. 331.4 ± 77.9mol/L, 229
respectively, p < 0.01), 18 months (301.9 ± 77.0 230
vs. 339.4 ± 90.7mol/L, respectively, p < 0.01) and 231
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Fig. 1. Consort diagram of Parkinson’s disease and control participants.
36 months (305.0 ± 76.4 vs. 331. ± 79.7mol/L,232
respectively, p < 0.05). Within groups, there was no233
significant change over time in urate concentrations234
for either PD or control participants using repeated235
measures analysis (p > 0.05). Four participants with236
PD and one control were taking allopurinol at base-237
line. For both PD and control participants, urate238
concentrations were significantly higher in males239
compared to females at each time point (p < 0.001240
for all, Supplementary Table 1).241
In comparison, the total plasma homocysteine242
concentration was significantly higher in those243
with PD than in controls at baseline (11.1 ± 3.8244
vs. 9.6 ± 3.3mol/L, respectively, p < 0.01), 18245
months (12.3 ± 3.8 vs. 11.1 ± 3.7mol/L, respec-246
tively, p < 0.05) and 36 months 13.9 ± 4.9 vs.247
12.3 ± 4.2mol/L, respectively, p < 0.05). However,248
repeated measures analysis showed plasma homo-249
cysteine significantly increased in both groups over 250
36 months (p < 0.01 for both). At baseline, females 251
control participants had significantly lower plasma 252
homocysteine concentrations compared to males 253
(8.8 ± 2.9 vs. 10.2 ± 3.5, respectively, p < 0.05) but 254
at no other time point. In PD participants, there were 255
no significant differences in males and females at 256
baseline, 18 and 36 months, but females had sig- 257
nificantly lower plasma homocysteine concentrations 258
compared to males at 54 months (11.4 ± 2.3 vs. 259
14.6 ± 5.0mol/L, respectively, p < 0.05). 260
At baseline, 73% of PD participants were lev- 261
odopa naı¨ve. Comparison of mean tests found no 262
significant differences between levodopa treated and 263
levodopa naı¨ve participants for serum urate con- 264
centrations (307.5 ± 71.2 vs. 301.3 ± 73.9mol/L, 265
respectively, p > 0.05) or serum homocysteine 266
concentrations (11.8 ± 3.4 vs. 10.9 ± 4.0mol/L, 267
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Table 1
Baseline demographic and clinical characteristics of the study participants
Control PD t/z p
Mean SD Mean SD
Age (years) 67.9 8.2 66.4 10.4 1.2 0.214
Education (years) 13.1 3.4 12.8 3.8 –1.1 0.251
NART 115.9 8.7 114.7 10.7 –0.3 0.770
PD duration (months) – – 6.4 6.0 – –
MDS-UPDRS III – – 26.9 12.1 – –
Hoehn and Yahr – – 2.0 0.7 – –
LEDD (mg/d) – – 178.0 148.2 – –
GDS-15 1.0 1.5 2.8 2.5 –6.87 <0.001
MoCA 27.0 2.5 25.2 3.7 –3.7 <0.001
MMSE 29.0 1.2 28.6 1.3 –2.7 0.006
BMI 27.7 3.9 27.2 4.8 0.8 0.411
Urate (mol/L) 331.4 83.8 302.7 77.9 –2.4 0.015
Homocysteine (mol/L) 9.6 3.3 11.1 3.8 –3.8 <0.001
Vitamin B12 (pg/mL) 472.6 171.1 391.5 170.0 –4.1 <0.001
Red cell folate (ng/ml) 324.4 162.0 277.2 148.5 –3.0 0.003
n % n % χ2 p
Sex (male) 54 54.5 100 64.9 2.7 0.098
Smoker 7 7.1 9 5.8 0.4 0.725
Hypertension 35 35.4 48 31.2 0.5 0.989
Type 2 diabetes mellitus 5 5.1 12 7.8 0.7 0.395
Ischaemic heart disease 9 9.1 18 11.7 0.4 0.514
Previous stroke or transient ischaemic attack 0 0.0 10 6.5 6.7 0.010
Hypercholesterolaemia 17 17.2 22 14.3 0.4 0.535
Gout 3 3.0 5 3.2 0 0.924
PD, Parkinson’s disease; SD, Standard deviation; NART, National Adult Reading Test; MDS UPDRS III, Movement Disorders Society
Unified Parkinson’s Disease Rating Scale Part III; LEDD, Levodopa equivalent daily dose; GDS-15, Geriatric Depression Scale; MoCA,
Montreal Cognitive Assessment; MMSE, Mini Mental State Examination. Significant results are highlighted in bold.
respectively, p > 0.05). However, urate concentration268
was significantly lower in levodopa naı¨ve PD par-269
ticipants compared to healthy controls (301.3 ± 73.9270
vs. 331.4 ± 83.8mol/L, respectively, p < 0.05),271
while homocysteine concentration was significantly272
higher (10.9 ± 4.0 vs. 9.6 ± 3.3mol/L, respectively273
<0.05).274
Baseline predictors of motor severity and275
cognition over 54 months276
Multivariate modelling was used to determine the277
effects of baseline homocysteine and urate on change278
in motor severity and change in cognition over 54279
months, respectively. Linear mixed effects modelling280
was used to predict motor severity (MDS-UPDRS281
III). After excluding non-significant predictors, age282
(= –4.0, p < 0.05), sex (= 0.2, p < 0.01) and time283
(= 5.2, p < 0.01) were controlled for in the basic284
model.285
The interaction of baseline urate with time was286
a significant predictor of change in MDS-UPDRS287
III score (p < 0.001), after controlling for B12 and288
folate concentrations, indicating that low urate levels289
at diagnosis were associated with declining motor290
severity (Table 2). Adding urate, urate × time and 291
covariates significantly improved the fit of the model 292
(χ2 = 437.1, p < 0.001). The basic model plus tHyc 293
and tHyc × time, controlling for LEDD, B12 and 294
folate, was also a significantly stronger model than 295
the basic model (χ2 = 405.1 p < 0.001). However, 296
only tHyc × time was significant predictor. There was 297
no significant difference in fit between these two 298
models (p > 0.05). Including both urate × time and 299
tHyc × time, controlling for LEDD, B12 and folate, 300
showed that both low urate and high tHyc predicted 301
declining motor severity (Table 2). However, the 302
model suggested that when taking into account both 303
urate and tHyc, baseline urate was the stronger pre- 304
dictor of change in motor severity (t = 3.5, p < 0.001 305
vs. t = 2.4, p < 0.05, respectively). The basic model 306
plus urate and homocysteine had stronger predic- 307
tive power than urate alone (χ2 = 77.2, p < 0.001) or 308
homocysteine alone (χ2 = 109.3, p < 0.001). 309
Baseline predictors of MoCA score over 54 months 310
were age (= –0.16, p < 0.001), MDS-UPDRS III 311
score (= –0.05, p < 0.01), time (= 1.14, p < 0.01) 312
and MDS-UPDRS × time (= –0.03, p < 0.001) and 313
were included in the basic model. Due to sex 314
differences in baseline urate concentration, sex 315
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Table 2
Baseline predictors of motor severity over 54 months using linear
mixed effects modelling
 SE t p-value
Basic modela + urate
Urate –0.01 0.0 –0.8 0.422
Urate × Time 0.02 0.0 4.5 <0.001
Basic modelb + homocysteine
tHyc 0.48 0.3 1.7 0.094
tHyc × Time 0.44 0.1 3.8 <0.001
Basic modelb + urate + homocysteine
Urate –0.02 0.0 –1.0 0.313
tHyc 0.57 0.3 2.0 0.052
Urate × Time 0.02 0.0 3.5 <0.001
tHyc × Time 0.29 0.1 2.4 0.016
Motor severity determined by MDS-UPDRS III. Significant
predictors highlighted in bold. aCovariates included in model:
age, sex, folate, B12, time, folate × time and B12 × time.
bCovariates included in model: age, sex, LEDD, folate, B12, time,
LEDD × time, folate × time and B12 × time. MDS-UPDRS III,
Movement Disorder Society Unified Parkinson’s Disease Rating
Scale Part III; LEDD, Levodopa equivalent daily dose; tHyc, serum
homocysteine.
Table 3
Baseline predictors of global cognition over 54 months using linear
mixed effects modelling
 SE t p-value
Basic modela + urate
Urate 0.00 0.00 –1.03 0.305
Urate × Time 0.00 0.00 1.38 0.170
Basic modelb + homocysteine
tHyc –0.05 0.09 –0.53 0.598
tHyc × Time 0.12 0.04 2.89 0.004
Basic modelb + urate + homocysteine
Urate –0.01 0.00 –1.13 0.261
tHyc –0.04 0.09 –0.42 0.678
Urate × Time 0.00 0.00 0.94 0.346
tHyc × Time 0.11 0.04 2.70 0.007
Global cognition determined by MoCA. Significant predictors
highlighted in bold. aCovariates included in model: sex, age,
MDS-UPDRS III, folate, B12, time, folate × time and B12 × time.
bCovariates included in model: sex, age, MDS-UPDRS III, LEDD,
folate, B12, time, LEDD × time, folate × time and B12 × time.
MoCA, Montreal Cognitive Assessment; MDS-UPDRS III, Move-
ment Disorder Society Unified Parkinson’s Disease Rating Scale
Part III; LEDD, Levodopa equivalent daily dose; tHyc, serum
homocysteine.
was controlled for in the basic model. Urate and316
urate × time were not significant predictors of change317
in MoCA score (p > 0.05, Table 3). When tHyc and318
tHyc × time were added to the basic model, con-319
trolling for LEDD, B12 and folate, tHyc × time320
was a significant predictor of MoCA score over321
time (Table 3) and the model significantly improved322
(χ2 = 230.0, p < 0.001).323
DISCUSSION 324
We found that participants with early PD had lower 325
serum urate and higher serum homocysteine than age- 326
matched controls. Mixed effect modelling revealed 327
that lower urate and higher homocysteine at baseline 328
predicted worse motor scores over 54 months, while 329
only high baseline homocysteine predicted declining 330
MoCA scores. 331
In keeping with previous studies, our cohort of PD 332
participants had significantly lower serum urate con- 333
centrations than controls [6, 21]. These studies also 334
found a correlation between lower baseline urate and 335
worsening motor function; however, our study design 336
differed in a number of ways. While we recruited 337
patients with mean disease duration of six months, 338
the other studies recruited PD patients, who did not 339
require levodopa, with disease duration of up to 340
five years. Our end-point was a motor progression 341
over 54 months using the MDS-UPDRS III, whilst 342
the end-point in others studies was the initiation of 343
dopaminergic therapy over the two-year follow up 344
period. 345
Low serum urate concentration predicted worsen- 346
ing motor symptoms over 54 months. The protective 347
effect of urate is thought to relate to its abil- 348
ity to act as a physiological buffer to oxidative 349
stress [3]. Evidence from human post-mortem stud- 350
ies suggests dopaminergic neurons in the substantia 351
nigra of PD patients are subject to higher levels of 352
oxidative stress than controls [1]. Rodents have an 353
enzyme, urate oxidase, which breaks down urate; 354
urate oxidase is not present in humans. Transgenic 355
urate oxidase knockout mice, who consequently have 356
higher levels of circulating urate, were shown to 357
lose fewer nigral dopamine neurons in response to 358
an intrastriatal injection of the dopaminergic toxin 359
6-hydroxydopamine, than wild-type mice [22]. Our 360
findings provide further evidence of the effects of 361
urate on progression of PD even in early disease, 362
and therefore, its role as a possible therapeutic tar- 363
get. A recent placebo controlled trial has shown that 364
inosine administration increases urate concentration 365
and oxidative capacity in patients with early PD [23]. 366
The increased oxidative capacity, as measured by 367
the ferric reducing property of plasma assay, was 368
associated with reduced change in the UPDRS III 369
over six months. This result provides evidence of the 370
therapeutic potential of inosine to increase urate con- 371
centration, although further longitudinal evaluation 372
is needed. 373
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Homocysteine was significantly higher in newly374
diagnosed PD compared to controls. This is consis-375
tent with a previous study in established PD [24].376
Homocysteine was also associated with increasing377
motor severity and cognitive impairment. This is378
consistent with the findings of O’Suilleabhain and379
colleagues [25] who reported that in patients with380
established PD, those with hyperhomocysteinaemia381
performed worse on a range of neuropsychomet-382
ric tests despite comparable motor severity. 20% of383
patients with hyperhomocysteinaemia in the original384
cohort were not included in the longitudinal anal-385
yses, however, because of excess mortality in this386
group.387
Increasing evidence suggests that the pathology388
of PD dementia includes a synergistic effect of389
-synuclein and amyloid pathologies. Post-mortem390
studies of PD subjects have shown that there is a391
significant correlation between the extent of amyloid392
deposition and Lewy body pathology [26]. Interest-393
ingly, in the EXPRESS trial, patients with PDD and394
hyperhomocysteinaemia showed a more favourable395
response to rivastigmine therapy on measures of396
cognition, functioning and neuropsychiatric symp-397
tomatology than those in the normal range [27],398
suggesting that stratifying patients by homocysteine399
level may be useful for predicting response to treat-400
ment.401
While raised plasma homocysteine is an estab-402
lished risk factor for cardiovascular disease [28],403
its role in diseases of the nervous system if still404
under investigation. Homocysteine acts as an N-405
Nitrosodimethylamine (NMDA) receptor agonist on406
cultured cortical neurons, leading to neuronal death407
[29]. In the basal ganglia, five days of homocysteine408
administration into the lateral ventricle of rats led to409
reduced levels of striatal dopamine and metabolites,410
and a decreased number of spontaneous movements411
[30]. One possible mechanism for this is increased412
oxidative stress; Bhattacharjee et al. has shown that413
60 days of systemic administration of homocysteine414
increases striatal levels of superoxide dismutase [31].415
Strengths of the current study include the recruit-416
ment of a cohort of patients with early PD, many of417
whom had low levels of motor impairment and not418
yet established on levodopa therapy. The inclusion of419
a matched control group was important to control for420
the effects of normal ageing. The study also used a421
range of validated assessments, which were repeated422
every 18 months.423
Potential limitations of this study include the non-424
inclusion of patients who declined to be part of the425
ICICLE-PD study. The participants who declined to 426
take part in the study may have been those with more 427
rapid motor and cognitive decline and therefore of 428
particular interest. Our homocysteine and urate levels 429
were based on a single non-fasting measurement and 430
fluctuations in homocysteine levels over time may 431
be important. A single homocysteine measurement 432
may underestimate the risk of the outcome of inter- 433
est due to regression dilution bias [32]. Although 434
this study is large in comparison to other studies 435
in PD, our sample size is small in comparison to 436
studies of non-PD populations [8, 33]. Nevertheless, 437
we were still able to demonstrate that impaired cog- 438
nition was associated with increased homocysteine 439
levels. 440
Only a small proportion of PD participants were 441
drug naive (12.3%) at baseline and our cohort con- 442
tained a mixture of participants on and off levodopa 443
therapy. This could have implications for our results 444
as previous studies have shown that levodopa acutely 445
increases homocysteine concentration [34]. How- 446
ever, we controlled for LEDD as part of our analysis 447
to minimise the effects. As with many longitudinal 448
studies, missing data was an issue; 58% of PD partic- 449
ipants and 68% of controls completed assessments at 450
each time point. This has implications for data inter- 451
pretation as participants who did not return for further 452
evaluation may have been those with a more rapid 453
decline in PD and cognition, and would therefore 454
have been of particular interest to this study. How- 455
ever, we used mixed effects modelling as part of our 456
analysis. This form of multilevel modelling has the 457
ability to handle missing data points, and so the omis- 458
sion of individual variables at one time point does not 459
result in all of the data for that subject being excluded 460
from analysis. 461
In conclusion, we have shown that in a longitudinal 462
study of PD subjects, urate and homocysteine predict 463
motor progression over 54 months, while homocys- 464
teine predicted cognitive decline. These findings lend 465
support to the hypothesis that oxidative stress may 466
play a role in the pathophysiology of PD and that 467
motor and cognitive aspects of the disease may have 468
overlapping but separate mechanisms. This hypoth- 469
esis would require further investigation in order to 470
develop robust neuroprotective strategies to alter the 471
disease trajectory. In addition to potential disease 472
modification, our findings suggest that determining 473
urate and homocysteine concentration at the out- 474
set may have a role in predicting patients with PD 475
at greater risk of decline in motor and cognitive 476
function. 477
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